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A case of Galloway-Mowat syndrome with novel 
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The combination of central nervous system abnormalities and renal impairment is a notable characteristic of Galloway-
Mowat syndrome (GAMOS), a disease which often accompanies microcephaly, developmental delay, and nephrotic syn-
drome. Many subtypes exist having various phenotypes and genotypes, and many genetic causes are still being identified. 
An 18-month-old boy first visited our clinic for seizure, delayed development, and microcephaly. During follow-up visits he 
developed proteinuria and nephrotic syndrome at the age of 6. Nephrotic syndrome became refractory to treatment. These 
phenotypes were suggestive of GAMOS. Next generation sequencing was performed for genetic analysis and revealed novel 
compound heterozygous variants in the WDR4 gene: c.494G>A (p.Arg165Gln) and c.540C>G (p.Ile180Met). This is the first 
case in Korea of GAMOS involving the WDR4 gene.
Key words: Galloway-Mowat syndrome, Microcephaly, Growth retardation, Cerebellar diseases, Nephrotic syndrome, 
WDR4.
Case Report
J Genet Med 2020;17(2):97-101
https://doi.org/10.5734/JGM.2020.17.2.97
ISSN 1226-1769 (Print) 2383-8442 (Online)
Introduction
Galloway-Mowat syndrome (GAMOS) is a disease first re-
ported in 1968, defined by a spectrum of neurodevelopmental 
anomalies and renal-glomerular disease [1]. Clinically, the syn-
drome is characterized by central nervous system (CNS) abnor-
malities such as microcephaly, developmental delay, seizures, 
and cerebellar atrophy. Renal features include proteinuria and 
nephrotic syndrome with variable age of onset, which are often 
refractory to treatment [2]. 
It is a phenotypically and genetically heterogenous disease, 
with subtypes 1 to 8 discovered so far [3]. Variants in the gene 
WDR73 were first identified in 2014, leading to the definition of 
subtype GAMOS1 [2]. In 2017, additional variants in LAGE3, OS-
GEP, TP53RK, and TRPKB were discovered as the genetic causes 
of GAMOS syndromes 2-5, respectively [4]. In 2018, Braun et al. 
[5] first reported the homozygous variants in the gene WDR4 
as the cause of GAMOS6 (MIM 618347) in a case of an Indian 
family with neurologic and renal abnormalities. Previously, two 
cases in 2015 and 2018, respectively, reported WDR4 gene vari-
ants causing microcephaly and growth retardation, but neither 
exhibited renal features, which is one of the important clinical 
features of GAMOS [5,6]. Thus, up to date, only one case has 
been reported with WDR4 as the cause of GAMOS6 [5]. 
Here we report the first case in Korea of GAMOS6 with novel 
compound heterozygous WDR4 gene variants responsible for its 
cause.
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Case
The patient was the second child of non-consanguineous par-
ents. He was delivered by cesarean section weighing 1,420 g due 
to premature rupture of membrane at 30 weeks’ gestation. He 
was hospitalized in the neonatal intensive care unit for 50 days 
due to apnea. Craniosynostosis was present at birth. He pre-
sented bilateral cryptorchidism and micropenis and had orchio-
pexy at 15 months. He showed severe developmental delays. He 
has achieved full head control at 10 months and rolled over at 
11months. He could sit down with support at 20months. At 18 
months, first seizure occurred, but electroencephalographies 
showed no remarkable findings. 
He repeated afebrile seizures and was referred to our clinic at 
the age of 27 months due to seizures and delayed development. 
Microcephaly and failure to thrive were present at the initial 
visit, with a head circumference of 39.5 cm at 27 months, which 
was below 3rd percentile. Height (79 cm) and weight (7.5 kg) 
were also below 3rd percentile. Some dysmorphic features were 
present as well, such as narrow forehead, frontal bossing, and 
short neck. The child could not meet the age-appropriate devel-
opmental milestones. The patient could not sit without support 
and crawling was not possible. His hand grasp was weak, and 
the child could barely babble and could not say a single mean-
ingful word. Initial laboratory tests showed no remarkable find-
ings except for lactic acidosis. Thyroid function tests were within 
normal limits. Brain magnetic resonance imaging (MRI) showed 
cerebral atrophy, cerebellar atrophy along with thinning of cor-
Fig. 1. T2-weighted magnetic resonance 
imaging of Galloway-Mowat syndrome 
with novel heterozygous WDR4 variants in 
a Korean boy at the age of 3 years (A-C) 
and 9 years (D-F). (A) Cerebellar atrophy 
with mild edema was noted on axial view. 
(B) An axial image showed no significant 
signal intensity at both putamen. (C) A sag-
ittal view showed cerebellar atrophy and 
cerebral atrophy with thinning of corpus 
callosum. (D) Cerebellar atrophy became 
more prominent compared to Fig. 1A. (E) 
An axial image showed newly developed 
hyperintensity at both putamen. (F) A sag-
ittal view showed progressed cerebellar 
atrophy and thinning of corpus callosum.
Fig. 2. Growth charts of the patient.
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pus callosum at 3 years of age (Figs. 1A-C). 
At 5 years, the patient developed occasional mild proteinuria 
(1+) with no associated symptoms. And at the age of 6 years, he 
was admitted for lethargy and generalized edema accompanied 
by hypoalbuminemia (2.5 mg/dL), proteinuria (3+) and increased 
urine protein-to-creatinine ratio (3.0). He was referred to a pedi-
atric nephrologist and was diagnosed with nephrotic syndrome. 
Steroid therapy was initiated and shown to be effective at first, 
but later its dependency required addition of an ACE inhibitor. 
Regardless of the medication, the patient’s nephrotic syndrome 
showed repeated rounds of exacerbation and improvement over 
the years. 
At 9 years, He still had severe growth retardation with a severe 
microcephaly; head circumference was 42 cm (<3 percentile), 
height and weight were 95 cm (<3 percentile) and 12 kg (<3 
percentile) (Fig. 2). Development was stagnated, with indepen-
dent sitting still not being possible and first word yet to be spo-
ken. A follow-up MRI showed the progressed cerebral and cer-
ebellar atrophy, and hyperintensity at both putamen was newly 
found (Figs. 1D-F). Seizures continued, for which the patient 
was treated with anti-epileptic drugs. And nephrotic syndrome 
showed occasional exacerbation. We performed whole-exome 
sequencing in trios (proband, mother, and father) to determine 
the cause of his multi-organ manifestation. 
We identified compound heterozygous variants in the 
WDR4  gene NM_033661:c.540C>G (p.Ile180Met) and 
NM_033661:c.494G>A (p.Arg165Gln). The variants were clas-
sified as variants of uncertain significance according to the 
guidelines of the American College of Medical Genetics and 
Genomics [7]. However, in silico analysis by SIFT predicted these 
variants were deleterious, and PolyPhen suggested the variants 
were probably damaging [8]. ExAc allele frequency for each vari-
ant was 0.0000. The arginine residue at codon 165 and the iso-
leucine residue at codon 180 were highly conserved throughout 
evolution (Fig. 3A). A segregation study showed both parents 
as carriers of the variant, thus leading to the diagnosis of novel 
compound heterozygous variants (Fig. 3B). The variants were 
confirmed by Sanger sequencing in proband and both parents, 
proving that WDR4 variants were responsible for the patient’s 
phenotypes and attributable to GAMOS6.
 After genetic diagnosis, the patient maintains the supportive 
cares on a multi-disciplinary approach: neurology, nephrology, 
endocrinology, ophthalmology, and nutrition. At the age of 12, 
seizure frequency remains unchanged, and nephrotic syndrome 
is controlled with steroid and ACE inhibitor. Growth retardation 
persists, with a height of 101 cm (<3 percentile) and a weight of 
13 kg (<3 percentile) (Fig. 2). Development milestones show no 
improvement. 
This study was approved by the Institutional Review Board 
of Yonsei University Health System (3-2020-0374). Written in-
formed consent was waived. 
Discussion
The hallmark of GAMOS is its involvement in both the CNS 
and the kidneys. Since its first discovery in 1968, more than 60 
cases have been reported, exhibiting a wide spectrum of clinical 
phenotypes [1,9]. 
Fig. 3. (A) Complete evolutionary conservation of arginine 165 and isoleucine 180 of WDR4 gene. (B) Family pedigree. The novel compound het-
erozygous variants in WDR4 gene were confirmed by Sanger sequencing of the patient and his parents.
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Neurologic manifestations varied in severity. Some children 
were able to attend school, though their scholastic performanc-
es were impaired, while others did not show any developmental 
progress [5]. Seizures were present in some patients but not all. 
However, all patients manifested microcephaly and global de-
velopmental delay, as in the patient of this case. Imaging studies 
showed cerebral atrophy, gyral abnormalities, and cerebellar 
atrophy in some patients. 
Renal involvement in GAMOS is characterized by proteinuria. 
Severity and onset of symptoms may also vary, from congenital 
nephrotic syndrome to mild, persistent proteinuria [5]. Often 
nephrotic syndrome in GAMOS is resistant to steroid therapy 
and progresses to end-stage renal disease requiring dialysis [2]. 
Nephrotic syndrome in our patient was not controlled well, be-
coming refractory to treatment over time. Renal biopsy was not 
done in this case; however other studies revealed histological 
findings of minimal change disease, mesangial cell proliferation, 
mesangial sclerosis, and focal segmental glomerulosclerosis, 
suggesting histological heterogeneity [10]. 
The gene WDR4 encodes tRNA-methytransferase noncatalyt-
ic subunit WDR4, an enzyme which is required for the 7-meth-
ylguanosine modification of tRNA [11]. Phenotypic features of 
WDR4 gene variants include growth deficiency, microcephaly, 
developmental delay, and intellectual disability [5]. Previously, 
this gene was often known to be associated with primordial 
dwarfism with various phenotypes [12]. Recently, two inde-
pendent publications reported autosomal recessive variants in 
WDR4 in patients with microcephalic primordial dwarfism, and 
microcephaly with growth retardation [6,12]. In 2018, Braun 
et al. [5] first reported a pathogenic WDR4 gene variant case 
with proteinuria and nephrotic syndrome. By inclusion of renal 
involvement, GAMOS, with its CNS and renal features, may 
comprise the phenotypic spectrum of pathogenic WDR4 gene 
variants [5]. Studies revealed that variants in genes involved in 
tRNA modifications, such as the KEOPS complex members, are 
responsible for the pathogenesis of GAMOS, and the fact that 
WDR4 encodes an enzyme required for tRNA modification adds 
support to these findings [4]. 
Table 1. Clinical features of WDR4-related GAMOS (in comparison with Braun et al. [5])
_ Patient # 1 Patient # 2 Patient # 3 Patient # 4 Patient #5
Sex Male N/A N/A Male N/A
Age (yr) 12 15 13 11 4
Weight 13 (–6Z) 18.9 (–6Z) 15.1 (–7Z) 13 (–8Z) 7 (–4Z)
Height 101 (–7Z) 122 (–5Z) 105 (–6Z) 98 (–6Z) 69 (–5Z)
Neurological 
   Intellectual disability Severe Moderate Mild Severe Severe
   Microcephaly + + + + +
   Seizures + – – – –
   Brain imaging +, cerebellar atrophy – – +, normal –
Renal 
   Proteinuria +(3+) +(3+) +(2+) +(3+) –
   Nephrotic syndrome + – – + –
      Onset 6 yr N/A N/A N/A N/A
      Treatment response Refractory N/A N/A Partial refractory N/A
Endocrinologic
   Growth retardation + + + + +
   TFT abnormalities – + + + –
Etc.

















References Present study Braun et al. [5]
patient-22 
Braun et al. [5]
patient-23 
Braun et al. [5]
patient-21 
Braun et al. [5]
patient-24 
GAMOS, Galloway-Mowat syndrome; TFT, thyroid function test; N/A, not applicable.
Clinical characteristics of five GAMOS patients with WDR4 mutation.
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The clinical phenotypic characteristics of this case in com-
parison with patients from a report by Braun et al. [5] are shown 
in Table 1. These five patients are so far all of the reported cases 
GAMOS with WDR4. All patients showed growth retardation, in-
tellectual disability, microcephaly, and proteinuria. However, the 
severity of the phenotypes differed, such as mild to severe intel-
lectual disability. For renal involvement, some had proteinuria 
only while others had nephrotic syndrome which was refractory 
to treatment. There are suggestions that some phenotypes (e.g. 
nephrotic syndrome) are age-dependent and may develop over 
time, which is supported by the fact that our patient did not de-
velop proteinuria and nephrotic syndrome until the age of six [5].
In conclusion, our patient had clinical phenotypes that were 
attributable to GAMOS, which included microcephaly, develop-
mental delay, seizure, and refractory nephrotic syndrome. The 
identified novel compound heterozygous WDR4 gene variants 
in this patient could contribute to GAMOS-related genotype 
phenotype expansion.
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